Sarepta Therapeutics holds a leadership position in Duchenne muscular dystrophy (Duchenne) and is building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. In 2023, they launched their fourth therapy and the first ever gene therapy to treat Duchenne.
